Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study (Q44133531)

30 November 2017

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study (English)

1 reference

30 November 2017

0 references

1 reference

12

Jay N Cohn

1 reference

30 November 2017

Maylene Wong

1

1 reference

30 November 2017

Lidia Staszewsky

2

1 reference

30 November 2017

Roberto Latini

3

1 reference

30 November 2017

Simona Barlera

4

1 reference

30 November 2017

Alberto Volpi

5

1 reference

30 November 2017

Yann-Tong Chiang

6

1 reference

30 November 2017

Raymond L Benza

7

1 reference

30 November 2017

Sidney O Gottlieb

8

1 reference

30 November 2017

Thomas D Kleemann

9

1 reference

30 November 2017

Franco Rosconi

10

1 reference

30 November 2017

Pieter M Vandervoort

11

1 reference

30 November 2017

Val-HeFT Heart Failure Trial Investigators

13

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Journal of the American College of Cardiology

30 November 2017

1 reference

30 November 2017

40

1 reference

30 November 2017

5

1 reference

30 November 2017

970-975

1 reference

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902063-6

7 January 2021

10.1016/S0735-1097(02)02063-6

Identifiers

DOI

1 reference

30 November 2017

1 reference